stars 1 stars 2 stars 3

Helios Bioelectronics is the developer of a multi-patented electrochemical chip, the FET Chip, which identifies targeted elements such as viral proteins or nucleic acids that can be used to identify specific diseases such as COVID-19. Sometimes called "lab on a chip," this nanotechnology enables a vast amount of information to be gathered through assays processed at the point-of-care that would otherwise rely on detection via remote biological laboratories. Using its patented sample purification technology, GattaCo hasdeveloped a plasma separation tool, the A-PON™. The A-PON automatically separates plasma from whole blood collected from a finger-stick without needing a centrifuge. GattaCo is developing a blood analysis cartridge system that integrates its sample purification technology together with Helios Bioelectronics' FET Chip. This cartridge will be read by iAssay's SimpleTest™ base technology with an adaptor specifically developed for the Helios/GattaCo cartridge.

Helios Bioelectronics Questions

The Helios Bioelectronics annual revenue was $1 million in 2026.

Yi-Shao Liu is the COO of Helios Bioelectronics.

1 people are employed at Helios Bioelectronics.

The NAICS codes for Helios Bioelectronics are [54, 541].

The SIC codes for Helios Bioelectronics are [873, 87].

Top Helios Bioelectronics Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users